Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1631 1633 1799
This examiner grants 38% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18334530 | METHODS AND COMPOSITIONS FOR CIRCULAR RNA MOLECULES | Final Rejection | The University of North Carolina at Chapel Hill |
| 18065360 | MINI-PROMOTER | Non-Final OA | Vanderbilt University |
| 18314773 | USE OF AAV-EXPRESSED M013 PROTEIN AS AN ANTI-INFLAMMATORY THERAPEUTIC | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18191790 | AAV-BASED GENE THERAPY FOR MULTIPLE SCLEROSIS | Final Rejection | University of Florida Research Foundation, Incorporated. |
| 17272194 | GENE THERAPY FOR THE TREATMENT OF GALACTOSEMIA | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 16535042 | INDUCIBLE DNA BINDING PROTEINS AND GENOME PERTURBATION TOOLS AND APPLICATIONS THEREOF | Non-Final OA | Massachusetts Institute of Technology |
| 17973773 | VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | Final Rejection | Novartis AG |
| 18046327 | TAU MODULATORS AND METHODS AND COMPOSITIONS FOR DELIVERY THEREOF | Non-Final OA | The General Hospital Corporation |
| 18407298 | RECOMBINANT AAV VECTORS EXPRESSING OSTEOPROTECTIVE GENES, INCLUDING HAS2 AND LUBRICIN, USEFUL IN THE TREATMENT OF OSTEOARTHRITIS AND RELATED JOINT CONDITIONS IN MAMMALS | Non-Final OA | Genzyme Corporation |
| 17178972 | GENERATING GABAergic NEURONS IN BRAINS | Non-Final OA | The Penn State Research Foundation |
| 18563175 | CRISPR-CAS3 SYSTEMS FOR TARGETED GENOME ENGINEERING | Non-Final OA | CORNELL UNIVERSITY |
| 18336276 | EXPRESSION OF FOXP3 IN EDITED CD34+ CELLS | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 16605740 | OPTIMIZED LENTIVIRAL VECTOR FOR XLA GENE THERAPY | Final Rejection | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18512933 | CANCER-KILLING CELLS | Non-Final OA | LIFT BIOSCIENCES LTD |
| 18509634 | VECTOR-FREE DELIVERY OF GENE EDITING PROTEINS AND COMPOSITIONS TO CELLS AND TISSUES | Final Rejection | Avectas Limited |
| 18004241 | NOVEL TRANSPLANTATION CELLS HAVING REDUCED IMMUNOGENICITY | Final Rejection | GC CELL CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy